Literature DB >> 17081807

The placebo effect for gastroenterology: tool or torment.

Charles N Bernstein1.   

Abstract

Placebo generally has a negative connotation both in clinical practice and in clinical trials. In this report the nature of placebo is explored in general and in relation to gastrointestinal diseases. The goodness of placebo is highlighted. PubMed was searched for articles and commentaries on placebo and for systematic reviews on placebo. Selected placebo-controlled trials in gastroenterology were reviewed. There are 5 key components impacting the placebo response: patient characteristics, practitioner characteristics, practitioner-patient interaction, the nature of the illness being treated, and the treatment being applied and the setting in which it is applied. There are also a number of factors that constitute the placebo response and likely all apply to some extent. These include the natural history of the condition, a regression to the mean (accounting for fluctuation in measurements over time), other time effects (ie, patient learning to cope, practitioner gaining expertise), unidentified parallel interventions (ie, change in habits or exogenous stress), the placebo effect of the administered agent being compared with placebo, and the physiologic effects of the placebo. In summary, there are positive aspects to placebo. Clinicians treating patients with gastrointestinal diseases can harness aspects of the placebo response to improve patient outcomes. Clinical trial planners can harness aspects of the placebo response to design disease-specific trials that can minimize the placebo response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081807     DOI: 10.1016/j.cgh.2006.09.003

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

1.  Serum correlates of the placebo effect in irritable bowel syndrome.

Authors:  E Kokkotou; L A Conboy; D C Ziogas; M T Quilty; J M Kelley; R B Davis; A J Lembo; T J Kaptchuk
Journal:  Neurogastroenterol Motil       Date:  2009-12-22       Impact factor: 3.598

2.  Exploring the Strange New World of Non-Celiac Gluten Sensitivity.

Authors:  Benjamin Lebwohl; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2015-03-18       Impact factor: 11.382

Review 3.  Treatment of IBD: where we are and where we are going.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-12-09       Impact factor: 10.864

Review 4.  Effectiveness and safety of herbal medicines in the treatment of irritable bowel syndrome: a systematic review.

Authors:  Jun Shi; Yao Tong; Jian-Gang Shen; Hai-Xia Li
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 5.  Placebo responses in patients with gastrointestinal disorders.

Authors:  Frauke Musial; Sibylle Klosterhalfen; Paul Enck
Journal:  World J Gastroenterol       Date:  2007-07-07       Impact factor: 5.742

Review 6.  Placebo effect in clinical trial design for irritable bowel syndrome.

Authors:  Eric Shah; Mark Pimentel
Journal:  J Neurogastroenterol Motil       Date:  2014-04-30       Impact factor: 4.924

Review 7.  Placebo: a brief updated review.

Authors:  Alfredo Jose Pardo-Cabello; Victoria Manzano-Gamero; Emilio Puche-Cañas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-08-09       Impact factor: 3.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.